Post‐hoc safety/efficacy analyses from pediatric delgocitinib atopic dermatitis trials
Pediatrics International · 2024
DOI: 10.1111/ped.15798 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Pediatrics International, 2024. Verfasst von Tatsuki Fukuie und 4 weiteren Autor:innen. Beteiligte Einrichtung: Allergy Center, National Center for Child Health and Development, Tokyo, Japan. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Ointments. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Tobacco Inc, Torii Pharmaceutical.
Abstract (Originalsprache)
Background
Delgocitinib ointment is usually recommended for use in children at a concentration of 0.25%. However, there are no clear criteria for dosing, except that a 0.5% formulation may also be used, depending on symptom severity. Treatment of atopic dermatitis is based on combinations of topical corticosteroids, tacrolimus ointment, and delgocitinib ointment, but there are no reports on the safety of delgocitinib ointment when used in combination with other drugs.
Methods
This is a post‐hoc analysis of data from two delgocitinib ointment trials with pediatric atopic dermatitis patients. The efficacy and safety of the 0.25% and 0.5% formulations were compared. Efficacy and safety were evaluated after up to 4 and 56 weeks of treatment, respectively. The safety of delgocitinib ointment when used in combination with topical corticosteroids and/or tacrolimus ointment was investigated.
Results
The dose–response relationship was examined according to baseline disease severity. The proportions of subjects with mild disease who achieved cumulative investigator's global assessment of 0 (clear) or 1 (almost clear) were 46.2% (0.25% ointment), 71.4% (0.5% ointment), and 7.7% (vehicle). For subjects with moderate to severe disease, the corresponding proportions were 19.0%, 20.0%, and 0.0%, respectively. No overall differences were seen in the safety profiles of the 0.25% and 0.5% delgocitinib ointment doses, or in the safety profiles of the two doses relating to disease severity or to concomitant use of topical corticosteroids and/or tacrolimus ointment.
Conclusions
These analyses indicate that after up to 4 weeks of treatment, delgocitinib 0.5% ointment may be more effective than the 0.25% dose for mild atopic dermatitis, and that after up to 56 weeks of treatment, delgocitinib is well tolerated in a pediatric trial population when used as prescribed in combination with topical corticosteroids and/or tacrolimus ointment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Allergy Center, National Center for Child Health and Development, Tokyo, Japan.
- Medical Affairs Department, TORII Pharmaceutical Co Ltd, Tokyo, Japan.
- Department of Dermatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
ORCID-Profile: Hiroyuki Toyama
Förderung
- Japan Tobacco Inc
- Torii Pharmaceutical
Zitieren
APA
Fukuie, T., Toyama, H., Tanaka, M., Ohashi-Doi, K., & Kabashima, K. (2024). Post‐hoc safety/efficacy analyses from pediatric delgocitinib atopic dermatitis trials. Pediatrics International. https://doi.org/10.1111/ped.15798
Vancouver
Fukuie T, Toyama H, Tanaka M, Ohashi-Doi K, Kabashima K. Post‐hoc safety/efficacy analyses from pediatric delgocitinib atopic dermatitis trials. Pediatrics International. 2024. doi:10.1111/ped.15798
BibTeX
@article{Fukuie2024,
author = {Fukuie, Tatsuki and Toyama, Hiroyuki and Tanaka, Mai and Ohashi-Doi, Katsuyo and Kabashima, Kenji},
title = {Post‐hoc safety/efficacy analyses from pediatric delgocitinib atopic dermatitis trials},
journal = {Pediatrics International},
year = {2024},
doi = {10.1111/ped.15798}
}
EUVIMED